Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  fluorine F 18 fluorothymidine
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
Fluorothymidine F 18-Labeled Positron Emission Tomography in Finding Recurrent Disease in Patients With Primary Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: HCI20112, NCI-2010-00958, NCT00707343
Multi-tracer PET/CT in Predicting and Assessing Response in Patients with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Receiving Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: HCI74163, NCI-2014-02370, 74163, NCI-2014-02286, NCT02245217
Leuprolide Acetate in Improving Immune Recovery and 18F FLT PET/CT in Predicting Immune Recovery after Donor Bone Marrow Transplant in Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 9 to 55
Trial IDs: 11-C-0136, NCI-2013-01485, 110136, P10780, NCT01338987
FLT PET/CT in Measuring Response in Patients with Previously Untreated Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: EAI141, NCI-2015-00328, NCT02392429
18F-FLT PET Imaging in Assessing Tumors and Measuring Response in Younger Patients With Brain Tumors
Status: Active
Phase: Phase II
Type: Diagnostic
Age: 21 and under
Trial IDs: PBTC-N12, NCI-2013-00805, NCT01244737
AT13387 in Treating Patients with Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9875, NCI-2015-01681, 15-XXX, NCT02572453
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients with Advanced Solid Tumors
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: UW13112, NCI-2014-00944, NCT02146222
Multi-tracer PET in Imaging Patients with Brain Tumors
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: HCI31335, NCI-2014-01824, 31335, NCT00813566
[F-18] FLT PET in Measuring Tumor Response in Patients with Solid Tumors or Hematopoietic Cancer
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 2006-127, NCI-2015-01345, 0905007082, NCI-2015-01231, WSU-2006-127, PFIZER-WSU-2006-127, NCT00935090
Positron Emission Tomography-Computed Tomography in Monitoring Treatment in Patients with Diffuse Large B-Cell Lymphoma Receiving First-Line Therapy
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: LYMIMG0001, NCI-2012-02178, NCT01410630
Fluorothymidine-Labeled Positron Emission Tomography in Measuring Response in Patients With Previously Untreated Intermediate- or High-Risk Myelodysplastic Syndrome Receiving Azacitidine
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: HO10417, NCI-2012-00362, 2011-0285, 2011-0285-CP005, NCT01535456
18F-FLT-PET in Predicting Response in Patients with Metastatic Breast Cancer to the Brain Undergoing Whole Brain Radiation Therapy
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 12-039, NCI-2015-01799, NCT01621906
MRI in Measuring Biomarkers of Early Treatment Response in Patients With Osteosarcoma or Ewing Sarcoma
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 13 and over
Trial IDs: VICC SAR 1275, NCI-2013-01359, NCT01882231
FLT PET in Measuring Treatment Response in Patients with Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 18 and over
Trial IDs: 7536, NCI-2013-01380, NCT01928186
FLT-PET/MRI in Measuring Early Response in Patients with Metastatic Solid Tumors Receiving Treatment That Blocks Blood Flow to the Tumor
Status: Temporarily closed
Phase: No phase specified
Type: Diagnostic
Age: 18 and older
Trial IDs: CASE 3Y12, NCI-2013-01177, NCT02055586
18F-FLT PET/CT in Sparing Bone Marrow in Patients With Gynecologic Cancer Undergoing Radiation Therapy
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: UPCC 28813, NCI-2014-00861, 819177, NCT02108457
18F-FLT PET/CT in Measuring Cell Proliferation in Patients with Brain Tumors
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 7754, NCI-2013-02162, NCT02167204
FLT PET in Predicting Malignant Tumors in Patients with Neurofibromatosis Type I
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 10 and over
Trial IDs: 14-C-0163, NCI-2014-02502, P141559, NCT02211768
Start Over